1
|
Takeichi T, Muro Y, Akiyama M. Ichthyotic skin phenotype induced by the chronic activation of Toll-like receptor 2, and autoinflammation. Br J Dermatol 2023; 189:252. [PMID: 37067921 DOI: 10.1093/bjd/ljad122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 04/12/2023] [Indexed: 04/18/2023]
Abstract
We read with great interest ‘Chronic activation of Toll-like receptor 2 induces an ichthyotic skin phenotype’ by Tagoe et al.1 Their findings expand our recent understanding of how certain kinds of autoinflammation contribute to the pathogenesis of ichthyosis. Inspired by the report by Tagoe et al., we suggest that their unique autosomal recessive congenital ichthyosis in vitro models have several characteristics in common with autoinflammatory keratinization diseases.
Collapse
Affiliation(s)
- Takuya Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshinao Muro
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masashi Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
2
|
Tagoe H, Hassan S, Bliss E, Youssef G, Heywood W, Mills K, Harper JI, O'Shaughnessy RFL. Chronic activation of Toll-like receptor 2 induces an ichthyotic skin phenotype. Br J Dermatol 2023; 189:91-102. [PMID: 36972303 DOI: 10.1093/bjd/ljad095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 03/06/2023] [Accepted: 03/18/2023] [Indexed: 03/29/2023]
Abstract
BACKGROUND Ichthyosis defines a group of chronic conditions that manifest phenotypically as a thick layer of scales, often affecting the entire skin. While the gene mutations that lead to ichthyosis are well documented, the actual signalling mechanisms that lead to scaling are poorly characterized; however, recent publications suggest that common mechanisms are active in ichthyotic tissue and in analogous models of ichthyosis. OBJECTIVES To determine common mechanisms of hyperkeratosis that may be easily targeted with small-molecule inhibitors. METHODS We combined gene expression analysis of gene-specific short hairpin RNA (shRNA) knockdowns in rat epidermal keratinocytes (REKs) of two genes mutated in autosomal recessive congenital ichthyosis (ARCI), Tgm1 and Alox12b, and proteomic analysis of skin scale from patients with ARCI, as well as RNA sequencing data from rat epidermal keratinocytes treated with the Toll-like receptor 2 (TLR2) agonist Pam3CSK4. RESULTS We identified common activation of the TLR2 pathway. Exogenous TLR2 activation led to increased expression of important cornified envelope genes and, in organotypic culture, caused hyperkeratosis. Conversely, blockade of TLR2 signalling in keratinocytes from patients with ichthyosis and our shRNA models reduced the expression of keratin 1, a structural protein overexpressed in ichthyosis scale. A time course of TLR2 activation in REKs revealed that although there was rapid initial activation of innate immune pathways, this was rapidly superseded by widespread upregulation of epidermal differentiation-related proteins. Both nuclear factor kappa B phosphorylation and GATA3 upregulation was associated with this switch, and GATA3 overexpression was sufficient to increase keratin 1 expression. CONCLUSIONS Taken together, these data define a dual role for TLR2 activation during epidermal barrier repair that may be a useful therapeutic modality in treating diseases of epidermal barrier dysfunction.
Collapse
Affiliation(s)
- Hephzi Tagoe
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, UK
- Livingstone Skin Research Centre
| | - Sakinah Hassan
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, UK
- Livingstone Skin Research Centre
| | | | - Gehad Youssef
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, UK
- Livingstone Skin Research Centre
| | | | | | - John I Harper
- Livingstone Skin Research Centre
- Department of Immunobiology and Dermatology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Ryan F L O'Shaughnessy
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, UK
| |
Collapse
|
3
|
Experimental Models for the Study of Hereditary Cornification Defects. Biomedicines 2021; 9:biomedicines9030238. [PMID: 33652877 PMCID: PMC7996736 DOI: 10.3390/biomedicines9030238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 02/23/2021] [Indexed: 11/16/2022] Open
Abstract
Ichthyoses comprise a broad spectrum of keratinization disorders due to hereditary defects of cornification. Until now, mutations in more than 50 genes, mostly coding for structural proteins involved in epidermal barrier formation, have been identified as causes for different types of these keratinization disorders. However, due to the high heterogeneity and difficulties in the establishment of valid experimental models, research in this field remains challenging and translation of novel findings to clinical practice is difficult. In this review, we provide an overview of existing models to study hereditary cornification defects with focus on ichthyoses and palmoplantar keratodermas.
Collapse
|
4
|
Tommasi C, Rogerson C, Depledge DP, Jones M, Naeem AS, Venturini C, Frampton D, Tutill HJ, Way B, Breuer J, O'Shaughnessy RFL. Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin. J Invest Dermatol 2019; 140:774-784.e11. [PMID: 31626786 DOI: 10.1016/j.jid.2019.08.448] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 08/29/2019] [Accepted: 08/29/2019] [Indexed: 11/30/2022]
Abstract
Varicella zoster virus (VZV) is a skin-tropic virus that infects epidermal keratinocytes and causes chickenpox. Although common, VZV infection can be life-threatening, particularly in the immunocompromized. Therefore, understanding VZV-keratinocyte interactions is important to find new treatments beyond vaccination and antiviral drugs. In VZV-infected skin, kallikrein 6 and the ubiquitin ligase MDM2 are upregulated concomitant with keratin 10 (KRT10) downregulation. MDM2 binds to KRT10, targeting it for degradation via the ubiquitin-proteasome pathway. Preventing KRT10 degradation reduced VZV propagation in culture and prevented epidermal disruption in skin explants. KRT10 knockdown induced expression of NR4A1 and enhanced viral propagation in culture. NR4A1 knockdown prevented viral propagation in culture, reduced LC3 levels, and increased LAMP2 expression. We therefore describe a drug-able pathway whereby MDM2 ubiquitinates and degrades KRT10, increasing NR4A1 expression and allowing VZV replication and propagation.
Collapse
Affiliation(s)
- Cristina Tommasi
- Livingstone Skin Research Centre, Immunobiology and Dermatology, University College London Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Clare Rogerson
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, United Kingdom
| | - Daniel P Depledge
- Infection and Immunity, University College London, London, United Kingdom; Department of Microbiology, New York University, New York, New York
| | - Meleri Jones
- Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, United Kingdom; Infection and Immunity, University College London, London, United Kingdom
| | - Aishath S Naeem
- Livingstone Skin Research Centre, Immunobiology and Dermatology, University College London Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Cristina Venturini
- Infection and Immunity, University College London, London, United Kingdom
| | - Dan Frampton
- Infection and Immunity, University College London, London, United Kingdom
| | - Helena J Tutill
- Infection and Immunity, University College London, London, United Kingdom
| | - Benjamin Way
- Livingstone Skin Research Centre, Immunobiology and Dermatology, University College London Great Ormond Street Institute of Child Health, London, United Kingdom
| | - Judith Breuer
- Infection and Immunity, University College London, London, United Kingdom
| | - Ryan F L O'Shaughnessy
- Livingstone Skin Research Centre, Immunobiology and Dermatology, University College London Great Ormond Street Institute of Child Health, London, United Kingdom; Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, United Kingdom.
| |
Collapse
|
5
|
Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev 2019; 40:856-880. [PMID: 31587329 DOI: 10.1002/med.21637] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 08/20/2019] [Accepted: 08/21/2019] [Indexed: 12/14/2022]
Abstract
The murine double minute 2 (MDM2) oncogene exerts major oncogenic activities in human cancers; it is not only the best-documented negative regulator of the p53 tumor suppressor, but also exerts p53-independent activities. There is an increasing interest in developing MDM2-based targeted therapies. Several classes of MDM2 inhibitors have been evaluated in preclinical models, with a few entering clinical trials, mainly for cancer therapy. However, noncarcinogenic roles for MDM2 have also been identified, demonstrating that MDM2 is involved in many chronic diseases and conditions such as inflammation and autoimmune diseases, dementia and neurodegenerative diseases, heart failure and cardiovascular diseases, nephropathy, diabetes, obesity, and sterility. MDM2 inhibitors have been shown to have promising therapeutic efficacy for treating inflammation and other nonmalignant diseases in preclinical evaluations. Therefore, targeting MDM2 may represent a promising approach for treating and preventing these nonmalignant diseases. In addition, a better understanding of how MDM2 works in nonmalignant diseases may provide new biomarkers for their diagnosis, prognostic prediction, and monitoring of therapeutic outcome. In this review article, we pay special attention to the recent findings related to the roles of MDM2 in the pathogenesis of several nonmalignant diseases, the therapeutic potential of its downregulation or inhibition, and its use as a biomarker.
Collapse
Affiliation(s)
- Wei Wang
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas.,Drug Discovery Institute, University of Houston, Houston, Texas
| | - Jiang-Jiang Qin
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas
| | - Mehrdad Rajaei
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas
| | - Xin Li
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas
| | - Xiaoyi Yu
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas
| | - Courtney Hunt
- Drug Discovery Institute, University of Houston, Houston, Texas
| | - Ruiwen Zhang
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas.,Drug Discovery Institute, University of Houston, Houston, Texas
| |
Collapse
|
6
|
Karim N, Durbin-Johnson B, Rocke DM, Salemi M, Phinney BS, Naeem M, Rice RH. Proteomic manifestations of genetic defects in autosomal recessive congenital ichthyosis. J Proteomics 2019; 201:104-109. [DOI: 10.1016/j.jprot.2019.04.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 03/22/2019] [Accepted: 04/07/2019] [Indexed: 02/06/2023]
|
7
|
Heinz L, Kim GJ, Marrakchi S, Christiansen J, Turki H, Rauschendorf MA, Lathrop M, Hausser I, Zimmer AD, Fischer J. Mutations in SULT2B1 Cause Autosomal-Recessive Congenital Ichthyosis in Humans. Am J Hum Genet 2017; 100:926-939. [PMID: 28575648 DOI: 10.1016/j.ajhg.2017.05.007] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 05/05/2017] [Indexed: 12/30/2022] Open
Abstract
Ichthyoses are a clinically and genetically heterogeneous group of genodermatoses associated with abnormal scaling of the skin over the whole body. Mutations in nine genes are known to cause non-syndromic forms of autosomal-recessive congenital ichthyosis (ARCI). However, not all genetic causes for ARCI have been discovered to date. Using whole-exome sequencing (WES) and multigene panel screening, we identified 6 ARCI-affected individuals from three unrelated families with mutations in Sulfotransferase family 2B member 1 (SULT2B1), showing their causative association with ARCI. Cytosolic sulfotransferases form a large family of enzymes that are involved in the synthesis and metabolism of several steroids in humans. We identified four distinct mutations including missense, nonsense, and splice site mutations. We demonstrated the loss of SULT2B1 expression at RNA and protein levels in keratinocytes from individuals with ARCI by functional analyses. Furthermore, we succeeded in reconstructing the morphologic skin alterations in a 3D organotypic tissue culture model with SULT2B1-deficient keratinocytes and fibroblasts. By thin layer chromatography (TLC) of extracts from these organotypic cultures, we could show the absence of cholesterol sulfate, the metabolite of SULT2B1, and an increased level of cholesterol, indicating a disturbed cholesterol metabolism of the skin upon loss-of-function mutation in SULT2B1. In conclusion, our study reveals an essential role for SULT2B1 in the proper development of healthy human skin. Mutation in SULT2B1 leads to an ARCI phenotype via increased proliferation of human keratinocytes, thickening of epithelial layers, and altered epidermal cholesterol metabolism.
Collapse
|
8
|
Kinsler VA, Drury S, Khan A, Waelchli R, Rukaite G, Barnicoat A, Lench N, Harper JI, O'Shaughnessy RFL. A novel microdeletion in LOR causing autosomal dominant loricrin keratoderma. Br J Dermatol 2014; 172:262-4. [PMID: 25142840 PMCID: PMC4303979 DOI: 10.1111/bjd.13361] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- V A Kinsler
- Genetics and Genomic Medicine, UCL Institute of Child Health, 30 Guilford St, London, WC1N 1EJ, U.K; Paediatric Dermatology, Great Ormond St Hospital for Children, London, U.K
| | | | | | | | | | | | | | | | | |
Collapse
|